Scancell to present SCOPE trial data at AACR IO conference
Why we think this is neutral
The RNS announcement is a regulatory update about Scancell presenting data from its SCOPE trial at the AACR IO conference. There is no mention of any material financial impact to the business, so this would be considered a neutral update.
Key Points
- Scancell to present translational data from the Phase 2 SCOPE trial of SCIB1 at the 2025 AACR IO conference
- SCIB1 is being evaluated in combination with nivolumab and ipilimumab in the SCOPE trial for advanced unresectable melanoma
- The data demonstrates functional vaccine specific T cell responses for patients enrolled in the trial
Summary
The biotechnology company will present translational data from the Phase 2 SCOPE trial of its cancer vaccine SCIB1 at the upcoming AACR IO conference.
Scancell Holdings plc, a clinical stage biopharmaceutical company, announced that translational data from the SCOPE trial demonstrating SCIB1 combined with nivolumab and ipilimumab will be presented at the 2025 AACR IO conference. The SCOPE study is evaluating SCIB1, Scancell's lead ImmunoBody® DNA vaccine, in combination with checkpoint inhibitors in late-stage melanoma patients.
Key Dates
25 February 2025
General
Poster presentation at AACR IO conference
Impact Score: 6
GENERAL UPDATE